Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines - PubMed (original) (raw)

Clinical Trial

. 1986 Sep-Oct;77(5):367-70.

• PMID: 3024797

Clinical Trial

Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines

G Chaloner-Larsson et al. Can J Public Health. 1986 Sep-Oct.

No abstract available

PubMed Disclaimer

Similar articles

• Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7.
  Top FH Jr, Buescher EL, Bancroft WH, Russell PK. Top FH Jr, et al. J Infect Dis. 1971 Aug;124(2):155-60. doi: 10.1093/infdis/124.2.155. J Infect Dis. 1971. PMID: 4330998 Clinical Trial. No abstract available.
• Simultaneous oral administration of live adenovirus types 4 and 7 vaccines. Protection and lack of emergence of other types.
  Gooch WM 3rd, Mogabgab WJ. Gooch WM 3rd, et al. Arch Environ Health. 1972 Dec;25(6):388-94. doi: 10.1080/00039896.1972.10666192. Arch Environ Health. 1972. PMID: 4343867 No abstract available.
• Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans.
  Top FH Jr, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK, Buescher EL. Top FH Jr, et al. J Infect Dis. 1971 Aug;124(2):148-54. doi: 10.1093/infdis/124.2.148. J Infect Dis. 1971. PMID: 4330997 No abstract available.
• Current use and future directions of adenovirus vaccine.
  Gurwith MJ, Horwith GS, Impellizzeri CA, Davis AR, Lubeck MD, Hung PP. Gurwith MJ, et al. Semin Respir Infect. 1989 Dec;4(4):299-303. Semin Respir Infect. 1989. PMID: 2560582 Review.
• Oral adenoviral-based vaccines: historical perspective and future opportunity.
  Tucker SN, Tingley DW, Scallan CD. Tucker SN, et al. Expert Rev Vaccines. 2008 Feb;7(1):25-31. doi: 10.1586/14760584.7.1.25. Expert Rev Vaccines. 2008. PMID: 18251691 Review.

Cited by

• Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.
  Zheng Y, Lu Z, Ding J, Jiang N, Wang J, Yang J, Song J, Chen H, Fang L, Li H, Tian H, Wang G, Zheng J, Chai D. Zheng Y, et al. Cancers (Basel). 2022 Sep 17;14(18):4512. doi: 10.3390/cancers14184512. Cancers (Basel). 2022. PMID: 36139670 Free PMC article.
• Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
  Li X, Huang J, Kawamura A, Funakoshi R, Porcelli SA, Tsuji M. Li X, et al. Vaccine. 2017 May 31;35(24):3171-3177. doi: 10.1016/j.vaccine.2017.04.077. Epub 2017 May 5. Vaccine. 2017. PMID: 28483194 Free PMC article.
• Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
  Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. Rosenberg SA, et al. J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900. doi: 10.1093/jnci/90.24.1894. J Natl Cancer Inst. 1998. PMID: 9862627 Free PMC article. Clinical Trial.
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
  Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Chen PW, et al. J Immunol. 1996 Jan 1;156(1):224-31. J Immunol. 1996. PMID: 8598466 Free PMC article.
• Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.
  Morsy MA, Alford EL, Bett A, Graham FL, Caskey CT. Morsy MA, et al. J Clin Invest. 1993 Sep;92(3):1580-6. doi: 10.1172/JCI116739. J Clin Invest. 1993. PMID: 8376608 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information